226 results on '"Licitra, L"'
Search Results
2. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study
3. Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
4. Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study
5. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
6. MO-0717 Seasonality of radiotherapy efficacy for head & neck cancer patients: MACH-NC/MARCH meta-analyses
7. Genomic Adjusted Radiation Dose (GARD) Predicts Overall Survival and Outperforms AJCC 8th Edition in Prognostication of HPV-Positive Oropharyngeal Squamous Cell Carcinoma
8. ‘Rare cancers’: not all together in clinical studies!
9. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy
10. Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer
11. A Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-Associated Head and Neck Cancer With Implications for Treatment Deintensification and Immunotherapy
12. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
13. Organic phantom study of MRI-radiomic features repeatability and stability
14. OC-0642 A radiomics based prognostic model for patients with head and neck squamous cell carcinoma
15. PCN72 An EARLY Cost-Effectiveness Analysis of Xevinapant in Combination with Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in United States.
16. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
17. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib
18. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
19. Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
20. PH-0043: Age related toxicity and outcome in oropharyngeal and nasoparyngeal cancer patients
21. PO-1577: Baseline MRI-radiomics can predict overall survival in non endemic nasopharyngeal cancer patients
22. PD-0543: An externally validated prognostic CT radiomics model for head and neck cancer patients
23. PO-1798: Quality of radiotherapy treatment plans for locally advanced sinonasal tumors in a phase II trial
24. PD-0545: Validation of a predictive model for salivary dysfunction during chemo-IMRT for head-neck cancer
25. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
26. Arcagen: Molecular profiling of rare cancer patients – analysis of the pilot study (87 patients)
27. LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
28. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
29. Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study
30. Introducing Information on Saliva Microbiota into Toxicity Modeling: Preliminary Results from a Trial
31. Survey of the Adoption of the UICC/AJCC 8th Edition TNM for Head and Neck Cancer: The User’s Initial Experience
32. PO-0729 Prognostic factors analysis in a cohort of Nasopharyngeal cancer patients with 5-year follow-up
33. SP-0662 Immunotherapy in HNC – when and for whom, biomarkers of response
34. EP-1923 Dimensionality reduction of radiomic features using a clustering coherence-based approach
35. PO-165 Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract
36. SP-015 Current status of immunotherapy in Head and Neck cancer
37. PO-115 Radiomics-based prediction of response to induction chemotherapy in sinonasal cancer
38. PO-161 Mutational profile of epithelial, non-glandular sinonasal cancers into 2 prospective clinical trials
39. OC-042 Genomic characterization of oral premalignant lesions to identify high-risk molecular clusters
40. PO-160 Tumor and retropharyngeal nodal GTVs prognostic role in unresectable non-glandular sinonasal cancers
41. PO-112 Role of microbiota in predicting oral mucositis in head and neck cancer patients treated with IMRT
42. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma
43. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach
44. Primary chemotherapy and surgery in advanced oral cavity squamous cell carcinomas : retrospective analysis
45. Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)
46. Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial
47. KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)
48. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer
49. Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells
50. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.